ARB 在心力衰竭中的应用.pptVIP

* * * * * * * * Click to add text * * * * 缬沙坦 vs 安慰剂 绝大多数都在服用ACEI 生存率没有差别 事件发生率缬沙坦组明显为低 缬沙坦与ACEI联用降低事件发生率但不应该与ACEI及BB联用 Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial CHARM-Added: Study design McMurray JJV et al. Lancet. 2003;362:761-71. Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added Randomized, double-blind NYHA class II–IV, LVEF ≤40%, stable ACEI dose for ≥30 days N = 2548 Candesartan 32 mg qd n = 1276 Placebo n = 1272 Median follow-up: 41 months Primary outcome: CV death or hospitalization for HF